USP 795 and 797 Updates Impose Stricter Sterility Standards on Compounding Pharmacies

The United States Pharmacopeia (USP) published revised chapters USP <795> and USP <797> effective November 1, 2023, establishing more stringent sterile compounding standards for pharmacies. These updates directly affect wholesale drug distributors and third-party logistics providers supplying active pharmaceutical ingredients (APIs), excipients, and storage services to compounding pharmacies.

Regulatory Background

USP chapters <795> (Pharmaceutical Compounding—Nonsterile Preparations) and <797> (Pharmaceutical Compounding—Sterile Preparations) set enforceable standards under the Federal Food, Drug, and Cosmetic Act. The FDA references these chapters in its oversight of compounding pharmacies under Section 503A (traditional compounding) and Section 503B (outsourcing facilities). State boards of pharmacy incorporate USP standards into licensure requirements.

The November 2023 revisions represent the first major update to USP <797> since 2008. The revision process began in 2016 following a series of fatal fungal meningitis outbreaks traced to contaminated compounded sterile preparations from New England Compounding Center. FDA enforcement actions under 21 CFR Part 211 (cGMP for finished pharmaceuticals) and Section 503B drove the need for clearer, more rigorous sterile compounding standards.

Key Changes in USP <797>

The revised USP <797> introduces four risk-level categories for compounded sterile preparations (CSPs), replacing the previous three-tier system:

1. Category 1: Compounding in a segregated compounding area without a cleanroom (12-hour beyond-use date limit)
2. Category 2: Compounding in an ISO Class 5 environment within an ISO Class 7 cleanroom (standard sterile compounding)
3. Category 3: Complex or high-risk compounding requiring additional environmental controls
4. Immediate-use CSPs: Preparations administered within 12 hours, previously exempt from many requirements, now subject to more controls

New requirements include:

• Enhanced environmental monitoring: Viable and non-viable particle counts at defined intervals. ISO Class 5 primary engineering controls (PECs) must be tested every 6 months.
• Media fill testing: Personnel qualification requires successful completion of three consecutive media fills annually. Previously, media fills were recommended but not mandatory for all personnel.
• Beyond-use dating (BUD) restrictions: Category 1 CSPs limited to 12 hours at room temperature. Category 2 CSPs have revised storage limits based on sterility test results.
• Master formulation and compounding records: Documentation requirements now align with cGMP standards under 21 CFR Part 211.186 and 211.188.

USP <795> updates focus on water quality, component sourcing, and cleaning/sanitizing procedures for non-sterile compounding. The chapter now requires pharmacies to document supplier qualification for all ingredients, directly affecting wholesale distributors providing APIs and excipients.

Impact on Wholesale Drug Distributors and 3PLs

Compounding pharmacies must now verify that all components meet USP monograph standards or have certificates of analysis (CoAs). This shifts compliance burden upstream to wholesale distributors supplying APIs, excipients, and compounding supplies. Distributors must:

• Provide CoAs for every lot of API or excipient sold to compounding pharmacies
• Maintain traceability records linking lot numbers to source manufacturers
• Ensure ingredients are stored under conditions specified in USP chapters (temperature, humidity, light exposure)
• Document compliance with 21 CFR Part 211.84 (testing and approval or rejection of components)

Third-party logistics providers storing APIs for compounding pharmacies face new scrutiny. USP <795> and <797> require pharmacies to audit their suppliers' storage conditions. 3PLs must demonstrate:

• Temperature and humidity monitoring systems with documented calibration (21 CFR Part 211.160(b)(4))
• Segregated storage preventing contamination or mix-ups (21 CFR Part 211.80)
• Documented pest control and sanitation programs (21 CFR Part 211.56)

State boards of pharmacy are incorporating these requirements into distributor and 3PL licensure standards. Failure to meet USP standards can result in license suspension under state pharmacy practice acts, even if the entity holds an active FDA registration under 21 CFR Part 207. See the wholesale pharmaceutical distributors compliance guide for state-specific licensing requirements.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these, 1,234 hold active FDA establishment registrations under 21 CFR Part 207, but only 63 hold NABP accreditation (formerly VAWD). USP <795> and <797> compliance is not yet a standalone data point in the ColdChainCheck scoring model, as state boards of pharmacy have not uniformly adopted inspection protocols for the November 2023 revisions.

The average compliance score across all entities is 51/100, placing most distributors in the "Fair" tier. This reflects incomplete data availability rather than noncompliance — many distributors hold the necessary licenses but lack third-party verification through NABP or documented quality system inspections. The score distribution shows 281 entities (22%) in the "Good" tier (60-79 points) and 28 entities (2%) in the "Excellent" tier (80-100 points). These higher-scoring entities typically hold NABP accreditation and maintain multi-state licensure portfolios, both signals of robust quality systems that align with USP requirements.

73 entities in the directory have at least one FDA recall on record. While recalls are not inherently disqualifying, they indicate historical quality control gaps that may surface during compounding pharmacy audits of upstream suppliers. Pharmacies required to document supplier qualification under USP <795> should cross-reference recall history when selecting API and excipient sources.

Practical Steps for QA and Procurement Teams

• Verify distributor compliance posture before onboarding: Use the ColdChainCheck directory to confirm active state pharmacy board licenses, FDA registration status, and NABP accreditation. Entities scoring below 40 points require additional due diligence documentation.
• Request CoA documentation for all API and excipient lots: USP <795> Section 5.2 requires compounding pharmacies to document component identity and quality. Distributors unable to provide lot-specific CoAs within 48 hours present operational risk.
• Audit 3PL storage conditions annually: USP <797> Section 5 mandates environmental controls for ingredient storage. Request calibration records for temperature monitoring systems and sanitation SOPs. ColdChainCheck does not yet track environmental monitoring compliance — this must be verified through direct audit or third-party inspection reports.
• Monitor state board enforcement activity: State pharmacy boards enforce USP standards through licensure conditions. ColdChainCheck tracks state-level enforcement actions and warning letters. See the compliance guides section for updates on state-specific USP adoption timelines.

ColdChainCheck will add USP <795> and <797> compliance signals to entity profiles as state boards publish inspection data and NABP updates its accreditation criteria to reflect the November 2023 revisions.

Disclaimer: This article provides general information about USP chapter revisions and their regulatory implications. It is not legal or compliance advice. Consult your legal counsel, quality assurance team, and relevant state board of pharmacy for entity-specific compliance guidance.